Marshall评分可更好地预测创伤性脑损伤早期死亡

2013-01-14 佚名 EGMN

  芝加哥——北美放射学会(RSNA)2012年会上公布的一项获奖研究显示,与鹿特丹CT评分系统相比,Marshal CT评分系统能够更好地预测创伤性脑损伤(TBI)患者的早期死亡。   Marshall评分和鹿特丹评分是两种最常用的放射学评分系统,但两者对CT表现的分类不同。Marshall评分系统包括基底池状态、中线移位>5 mm及出血肿块,而鹿特丹评分系统包括基底池、中线移位>5 m

  芝加哥——北美放射学会(RSNA)2012年会上公布的一项获奖研究显示,与鹿特丹CT评分系统相比,Marshal CT评分系统能够更好地预测创伤性脑损伤(TBI)患者的早期死亡。

  Marshall评分和鹿特丹评分是两种最常用的放射学评分系统,但两者对CT表现的分类不同。Marshall评分系统包括基底池状态、中线移位>5 mm及出血肿块,而鹿特丹评分系统包括基底池、中线移位>5 mm、蛛网膜下腔出血和/或脑室内出血及硬膜外出血,但不包括出血肿块。

  在这项研究中,日本仙台市东北大学的放射科医生Daddy Mata Mbemba博士及其同事评估了245例连续就诊的轻至重度TBI患者的初始CT扫描结果和出院状态,旨在探讨Marshall评分和鹿特丹 评分是否与出院时死亡(即早期死亡)相关。纳入根据新奥尔良标准和/或加拿大头部CT准则被建议进行CT检查的轻度(定义为格拉斯哥昏迷量表评分13~15分)病例。患者的平均年龄为49岁(15~93岁),67%为男性。

  出院时,25例患者死亡,220例存活。至死亡的中位时间为3天(1~83天)。Logistic回归分析显示,与早期死亡独立相关的CT表现包括基底池状态[比值比(OR)= 771.5;P<0.001]、中线移位阳性(OR=56.2;P=0.0011)、出血肿块(OR =12.9;P=0.0065)、以及蛛网膜下腔出血和/或脑室内出血(OR=3.8;P=0.0394)。硬脑膜外出血存在与否并不是显著预测因素。

  Mbemba博士表示,Marshall评分和鹿特丹评分系统均包括无基底池和中线移位阳性这2个显著的早期死亡独立预测因素,但只有Marshall评分系统包括出血肿块这一额外的显著预测因素,这可能是Marshall评分系统预测TBI早期死亡的效果优于鹿特丹评分系统的原因。

查看原文:Marshall score better predictor of early TBI death  



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025412, encodeId=7df4202541243, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Tue Jul 02 04:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973236, encodeId=030419e3236cc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed Sep 11 04:56:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328838, encodeId=fee31328838d4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335040, encodeId=8c641335040af, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396741, encodeId=54a21396e41a2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
    2013-07-02 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=2025412, encodeId=7df4202541243, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Tue Jul 02 04:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973236, encodeId=030419e3236cc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed Sep 11 04:56:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328838, encodeId=fee31328838d4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335040, encodeId=8c641335040af, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396741, encodeId=54a21396e41a2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2025412, encodeId=7df4202541243, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Tue Jul 02 04:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973236, encodeId=030419e3236cc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed Sep 11 04:56:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328838, encodeId=fee31328838d4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335040, encodeId=8c641335040af, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396741, encodeId=54a21396e41a2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
    2013-01-16 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2025412, encodeId=7df4202541243, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Tue Jul 02 04:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973236, encodeId=030419e3236cc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed Sep 11 04:56:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328838, encodeId=fee31328838d4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335040, encodeId=8c641335040af, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396741, encodeId=54a21396e41a2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2025412, encodeId=7df4202541243, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Tue Jul 02 04:56:00 CST 2013, time=2013-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973236, encodeId=030419e3236cc, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Wed Sep 11 04:56:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328838, encodeId=fee31328838d4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335040, encodeId=8c641335040af, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396741, encodeId=54a21396e41a2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 16 01:56:00 CST 2013, time=2013-01-16, status=1, ipAttribution=)]

相关资讯

NEJM:金刚烷胺可加快脑损伤后意识恢复

     《新英格兰医学杂志》NEJM 3月1日发表的一项国际、随机、双盲、安慰剂对照研究显示,为期4周的金刚烷胺治疗能够加快创伤性脑损伤(TBI)后意识障碍患者的功能恢复速度[N. Engl. J. Med. 2012;366:819-26]。          在这项研究中,新泽西州JFK约翰逊康复研究所的Jo

LANCET NEUROL:创伤性脑损伤发病率高于官方公布的6倍

      一项最新的以人群为基础的研究表明,创伤性脑损伤(TBI)的真实发生率大约 比官方数字高6倍。这一研究结果发表于最新一期的《柳叶刀神经病学》杂志。        新西兰奥克兰理工大学首席研究员Valery Feigin教授在一份新闻稿中说:“我们研究是首次涵盖较多轻度TBI患者的研究,而此类研究通常不住

静推高渗液体对不显著改善严重TBI患者预后

  一项多国研究显示,对非低血容量性休克的严重创伤性脑损伤(TBI)患者,予高渗性液体不显著改善6个月时神经系统预后或生存率。研究发表于《美国医学会杂志》(JAMA) 2010, 304(13):1455。   研究选取1087例未达低血容量性休克标准的钝性外伤患者(年龄≥15岁,院前GCS≤8),分别给250 mL 7.5%盐水/6%右旋糖酐70,7.5%盐水或0.9%盐水静推, 观察病情改善率